Event Review Grand Affair for the Biopharmaceutical Technology Industry
The Vogel Biopharmaceutical Technology Forum 2022 (VBTF 2022) was successfully held in Shanghai, China on September 23. Organized by Pharmatec China, Shanghai Medipark and Pharma Champ, the event brought together professionals from the pharmaceutical industry to exchange and share the latest global trends and innovative technologies and solutions in biopharmaceutical R&D, production, engineering, and quality management.
According to Sullivan's statistics, the market size of the global biopharmaceutical industry reached RMB 2,160.4 billion in 2020, and the growth rate has been maintained at about 9 %~10 % in recent years; the market size of the Chinese biopharmaceutical industry has reached RMB 345.7 billion in 2020, and the growth rate has been as high as 19 %~20 % in recent years, far exceeding the global market growth rate.
In addition, based on data, China has contributed to the main increment of the global biopharmaceutical production capacity in recent years and is becoming the main undertaking of industrial transfer. From 2017 to 2020, the global biopharmaceutical production capacity increased from 16.794 million liters to 17.38 million liters, and the capacity increased by 3.96 %. Among them, the production capacity in China, Japan, India and other places has increased, especially the capacity of biopharmaceuticals in China increased by 975,000 liters, accounting for 77 % of the newly added capacity of biopharmaceuticals worldwide.
Insights into the latest global trends and innovative solutions
With the rapid development of the industry, VBTF 2022 has played the role of a professional technology exchange and cooperation platform, bringing together professionals from the pharmaceutical industry to exchange and share the latest global trends and innovative technologies and solutions in biopharmaceutical R&D, production, engineering, and quality management. The event also offered advice and suggestions for promoting the development of the industry.
At the opening ceremony, Zhou Baodong, Deputy Secretary of the Party Committee of Scientech Information and Publications (Stip), stated in a video speech, "The development of biopharmaceutical technology and the promotion of precision medicine research are emerging with rapid growth. It is hoped that this forum can build a platform for technical exchange and knowledge sharing for pharmaceutical colleagues, so as to accelerate the promotion of innovative biopharmaceutical equipment technology and solutions in China, and help biopharmaceutical enterprises solve problems and challenges encountered in R&D and production."
Ding Jianping, Director of Science and Technology Innovation and Development Committee of Baoshan District, said that the bio pharmaceutical industry in Baoshan District of Shanghai has developed rapidly, attracting more than 200 enterprises in the past two years. In 2021, the total output value of the bio pharmaceutical industry in Baoshan District reached 5.1 billion yuan, and the industrial investment in its Bio Pharmaceutical Industrial Park increased by 430 %. Baoshan District has the resources, talent, location and technical strength needed for the development of biomedicine.
“Medipark is committed to building a sustainable biomedical ecosystem,” emphasized Liu Tao, General Manager of Medipark, “This is the mission of Medipark, because the park is closely connected with biopharmaceutical enterprises, governments, investment and financing institutions, professional service institutions, and university and research institutes, and should play a greater role in building a sustainable biopharmaceutical ecosystem.” He sincerely welcomed everyone to visit the Baoshan Industrial Park for investment cooperation.
Pharma Champ is an equipment supplier in the field of clean fluid, with rich experience in project implementation. Luo Changhu, General Manager of Pharma Champ said that Pharma Champ has always attached great importance to technology in the development process, and hopes to join hands with upstream and downstream enterprises of biopharmaceuticals to make joint efforts for talent training and technological innovation in the industry, so as to jointly meet the current and future challenges and opportunities of the biopharmaceutical industry.
New Report on the Chinese Pharmaceutical CDMO Market 2022
The New Report on the Chinese Pharmaceutical CDMO Market 2022 was release at the forum. Zhang Fengjuan, the head of Pharmatec China project described that the whole report used six chapters and 53 charts to comprehensively reveal the development status and investment opportunities of the CDMO industry. In the report, it is revealed that the biomedical CDMO industry will generally maintain a rapid growth momentum in the next five years; at the same time, the industrial acquisition and merger, intelligence development and other trends will become more and more obvious.
Two sub-forums at the show
After the opening ceremony, two sub-forums, ‘Biopharmaceutical Engineering and Equipment’ and ‘Biopharmaceutical Process Development and Commercial Production’, were held simultaneously, and 17 speakers analyzed the latest technology trends and practical cases in the development of the biopharmaceutical industry for the audiences who participate in the forum at the site or online.
The presentation about hot topics such as the development of domestic equipment, GMP project validation management, single-use systems, and Car-T production process optimization provide ideas for the pharmaceutical industry to improve efficiency, reduce costs, ensure compliance, etc. Next year, the Vogel Biopharmaceutical Technology Forum 2023 will be held, expecting to discuss the latest issues in the biopharmaceutical field with colleagues in the industry.